Sun Pharma moves quickly to stamp executive authority on Ranbaxy

Sun Pharmaceutical Managing Director Dilip Shanghvi

India's Sun Pharmaceutical apparently wasted no time in announcing its current executives would be in charge of handling the merger of Ranbaxy Laboratories staff, facilities and operations into one unit.

Within days of receiving final clearance for the year-old acquisition, Sun founder and Managing Director Dilip Shanghvi circulated some names in an e-mail to employees of both companies, according to the Times of India.

Shanghvi said the leadership team members, who are to report to him, were selected during a two-year process. His email message said, "This leadership structure is effective from Day 1 of merger."

The message did not identify the team members or reveal any information about the mixture of executive and senior officials after the merger except to say Kal Sundaram, Sun's North America CEO, would remain in place to lead the merged company's operations in Canada and the United States. He also identified other Sun regional executives who would add the Ranbaxy business to their responsibilities in their areas.

Many Ranbaxy executives have left the company over the past year, but CEO and Managing Director Arun Sawhney was still at Ranbaxy. The newspaper quoted a spokesperson as saying "an appropriate role" for him at Sun was still being considered.

- here's the story from Times of India

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.